Last reviewed · How we verify
PRM-151
At a glance
| Generic name | PRM-151 |
|---|---|
| Also known as | recombinant human serum amyloid P, recombinant human pentraxin 2 |
| Sponsor | Hoffmann-La Roche |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (PHASE3)
- A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
- PRM-151 in the Prevention of Scarring Following Trabeculectomy (PHASE2)
- A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (PHASE1)
- A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRM-151 CI brief — competitive landscape report
- PRM-151 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI